Lexaria’s Oral Capsules Rival Injectable Weight Loss Treatment

Lexaria Bioscience ( (LEXX) ) has provided an announcement.

Lexaria Bioscience announced positive results from its Human Study #3, demonstrating that its oral DehydraTECH-tirzepatide capsules achieve comparable blood concentration levels to Eli Lilly’s injectable Zepbound® for weight loss. The study showed that the oral capsules not only matched the efficacy of the injections but also reduced adverse events by 47%, suggesting a promising alternative to injections. These findings support further investigation in an ongoing 12-week study in Australia, potentially establishing Lexaria as a significant player in the oral delivery market for weight loss and diabetes management.

More about Lexaria Bioscience

Lexaria Bioscience Corp. is a global innovator in drug delivery platforms, focusing on enhancing the delivery of active pharmaceutical ingredients through its patented DehydraTECH technology. The company is positioning itself within the fast-growing GLP-1 weight loss and diabetes control markets.

YTD Price Performance: -36.22%

Average Trading Volume: 152,139

Technical Sentiment Consensus Rating: Buy

Current Market Cap: $23.7M

For a thorough assessment of LEXX stock, go to TipRanks’ Stock Analysis page.